News
IMTX
10.77
-1.10%
-0.12
Immatics N.V.: An Intriguing Developmental Concern
Imatics N.V., a European T-Cell receptor therapy company, is expected to release clinical data on all four of its candidates in 2024. The company's main focus is on developing T-cell receptor therapies for the treatment of solid tumors. Immatics has collaborations with Bristol Myers Squibb totaling $4.2 billion in potential milestones. Shares of the company have traded below their initial trade in 2020.
Seeking Alpha · 5d ago
Weekly Report: what happened at IMTX last week (0422-0426)?
Weekly Report · 5d ago
Immatics: Big Pharma Partners, Intriguing Catalysts Make Buy Case
German biotech company Immatics achieved its Nasdaq listing in 2020. The company focuses on developing T-cell receptor-based immunotherapies for solid tumors with unmet medical needs. It has two major data readouts due in 2H24, and a pivotal study initiation in melanoma. The risk reward is attractive for investors in the company.
Seeking Alpha · 04/27 14:32
Immatics is Now Oversold (IMTX)
NASDAQ · 04/25 16:27
Weekly Report: what happened at IMTX last week (0415-0419)?
Weekly Report · 04/22 10:11
Weekly Report: what happened at IMTX last week (0408-0412)?
Weekly Report · 04/15 10:07
Weekly Report: what happened at IMTX last week (0401-0405)?
Weekly Report · 04/08 10:10
Weekly Report: what happened at IMTX last week (0325-0329)?
Weekly Report · 04/01 10:09
Maintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising Partnerships
TipRanks · 03/29 08:26
Weekly Report: what happened at IMTX last week (0318-0322)?
Weekly Report · 03/25 10:10
Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR)
3 analysts have recently maintained Buy ratings on Immatics, Vor Biopharma and Jazz Pharmaceuticals. The 3 stocks are in the Healthcare sector and are expected to make moves following their insider activities. 3 analysts just weighed in on  Immatics (IMTX – Research Report), Vor Bipharma (VOR – Research report) and Jazz pharmaceuticals with bullish sentiments.
TipRanks · 03/25 01:50
IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023
Immatics reported earnings per share of -32 cents for the fourth quarter of 2023. The company reported revenue of $17.14 million. This was above the analyst estimate of -35 cents. Immatics also reported better than expected revenue for the quarter.
Investorplace · 03/21 18:52
12 Health Care Stocks Moving In Thursday's Pre-Market Session
10 Bioscience (NASDAQ:YTEN) stock increased by 133.7% to $0.57 during Thursday's pre-market session. The company's market cap is at $5.2 billion. Immunovant and argenx stock moved upwards by 14.0% and 13.24% respectively. Losers Tourmaline Bio and Avinger stock decreased by 33.4% during the pre- market session.
Benzinga · 03/21 13:05
Immatics N.V. Showcases Clinical Strides and Fiscal Health
Immatics N.V. Has reported significant progress in its clinical trials. The company completed a public offering of $201.5 million and projects a financial runway into 2027. Immatics is preparing to initiate a Phase 2/3 trial for IMA203 GEN1 therapy.
TipRanks · 03/21 12:57
Weekly Report: what happened at IMTX last week (0311-0315)?
Weekly Report · 03/18 10:10
Weekly Report: what happened at IMTX last week (0304-0308)?
Weekly Report · 03/11 10:08
Big Pharma patent cliffs seen fueling oncology M&A this year
Big Pharma patent cliffs seen fueling oncology M&A this year. Around $182B in revenue is at risk over the next four years due to patent expirations. Cantor Fitzgerald sees between five and 17 acquisition deals for oncologists in 2014. The global market for cancer drugs is expected to grow from $180B in 2022 to $323B in 2028.
Seeking Alpha · 03/10 17:08
Buy Rating Affirmed for Immatics on Promising TCR-Based Cancer Therapies and Strategic Partnerships
TipRanks · 03/07 04:59
Tracking Baker Brothers Portfolio - Q4 2023 Update
Seeking Alpha · 03/06 22:09
Weekly Report: what happened at IMTX last week (0226-0301)?
Weekly Report · 03/04 10:10
More
Webull provides a variety of real-time IMTX stock news. You can receive the latest news about Immatics N.V through multiple platforms. This information may help you make smarter investment decisions.
About IMTX
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.